Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with
neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.